1. Antibiotic-eluting scaffolds with responsive dual-release kinetics facilitate bone healing and eliminate S. aureus infection.
- Author
-
Sheehy EJ, von Diemling C, Ryan E, Widaa A, O' Donnell P, Ryan A, Chen G, Brady RT, López-Noriega A, Zeiter S, Moriarty TF, and O' Brien FJ
- Subjects
- Animals, Rabbits, Mice, Vancomycin pharmacology, Vancomycin chemistry, Vancomycin administration & dosage, Durapatite chemistry, Kinetics, Wound Healing drug effects, Osteogenesis drug effects, Collagen chemistry, Female, Tissue Scaffolds chemistry, Anti-Bacterial Agents pharmacology, Anti-Bacterial Agents chemistry, Staphylococcal Infections drug therapy, Osteomyelitis drug therapy, Staphylococcus aureus drug effects, Gentamicins pharmacology, Gentamicins administration & dosage, Gentamicins chemistry, Gentamicins therapeutic use
- Abstract
Osteomyelitis (OM) is a progressive, inflammatory infection of bone caused predominately by Staphylococcus aureus. Herein, we engineered an antibiotic-eluting collagen-hydroxyapatite scaffold capable of eliminating infection and facilitating bone healing. An iterative freeze-drying and chemical crosslinking approach was leveraged to modify antibiotic release kinetics, resulting in a layered dual-release system whereby an initial rapid release of antibiotic to clear infection was followed by a sustained controlled release to prevent reoccurrence of infection. We observed that the presence of microbial collagenase accelerated antibiotic release from the crosslinked layer of the scaffold, indicating that the material is responsive to microbial activity. As exemplar drugs, vancomycin and gentamicin-eluting scaffolds were demonstrated to be bactericidal, and supported osteogenesis in vitro. In a pilot murine model of OM, vancomycin-eluting scaffolds were observed to reduce S. aureus infection within the tibia. Finally, in a rabbit model of chronic OM, gentamicin-eluting scaffolds both facilitated radial bone defect healing and eliminated S. aureus infection. These results show that antibiotic-eluting collagen-hydroxyapatite scaffolds are a one-stage therapy for OM, which when implanted into infected bone defects simultaneously eradicate infection and facilitate bone tissue healing., Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:Eamon J Sheehy has patent #17773914 pending to The Royal College of Surgeons in Ireland. Amro Widaa has patent #17773914 pending to The Royal College of Surgeons in Ireland. Alan Ryan has patent #17773914 pending to The Royal College of Surgeons in Ireland. Adolfo Lopez-Noriega has patent #17773914 pending to The Royal College of Surgeons in Ireland. Fergal O’ Brien has patent #17773914 pending to The Royal College of Surgeons in Ireland. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2025
- Full Text
- View/download PDF